Literature DB >> 14688800

Portal tract fibrogenesis in the liver.

Giuliano Ramadori1, Bernhard Saile.   

Abstract

The portal area is the 'main entrance' and one of the two main exits of the liver lobule. Through the main entrance portal and arterial blood reach the liver sinusoids. Through the exit the bile flows towards the duodenum. The three main structures, portal vein and artery with their own wall (and vascular smooth muscle cells) and bile duct with its basal membrane, are surrounded by loose myofibroblasts and by the first layer of hepatocytes and non-parenchymal cells. Chronic diseases of the liver can lead to development of liver cirrhosis, characterized by formation of fibrotic septa which can be portal-portal in the case of the chronic biliary damage or portal-central in the case of the chronic viral hepatitis. Central-central septa can also be observed under other pathological conditions. When damaging noxae are introduced to the liver, inflammatory cells are first recruited to the portal field, the first layer of hepatocytes may be destroyed (enlargement of the portal field) and portal (myo)fibroblasts become activated. A similar reaction may take place when the target of inflammation is the bile duct with consecutive reduction of the bile flow, activation of the portal (myo)fibroblasts, proliferation of bile ducts and destruction of the hepatocytes around the portal field. Increased matrix deposition may be the consequence. During the past years several publications dealt with the pathomechanisms of portal fibrogenesis as well as with its resolution. One of the most intriguing observations was that it is not hepatic stellate cells of the hepatic sinusoid, but portal (myo)fibroblasts which rapidly acquire the phenotype of 'activated' (myo)fibroblasts in the early stages of cholestatic fibrosis. These may also become the main mesenchymal cells of the porto-portal or porto-central fibrotic septa. This article reviews the similarities as well as differences between the mesenchymal cells of the portal tract and of the fibrotic septa vs 'activated' stellate cells of the hepatic sinusoids, and discusses the debate over their relative contributions to liver fibrogenesis.

Entities:  

Mesh:

Year:  2004        PMID: 14688800     DOI: 10.1038/labinvest.3700030

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  47 in total

Review 1.  Biliary wound healing, ductular reactions, and IL-6/gp130 signaling in the development of liver disease.

Authors:  A-J Demetris; John-G Lunz; Susan Specht; Isao Nozaki
Journal:  World J Gastroenterol       Date:  2006-06-14       Impact factor: 5.742

Review 2.  Recent advances in the pathogenesis and diagnosis of liver fibrosis.

Authors:  Natalie J Török
Journal:  J Gastroenterol       Date:  2008-07-01       Impact factor: 7.527

Review 3.  Novel insights into the function and dynamics of extracellular matrix in liver fibrosis.

Authors:  Morten A Karsdal; Tina Manon-Jensen; Federica Genovese; Jacob H Kristensen; Mette J Nielsen; Jannie Marie B Sand; Niels-Ulrik B Hansen; Anne-Christine Bay-Jensen; Cecilie L Bager; Aleksander Krag; Andy Blanchard; Henrik Krarup; Diana J Leeming; Detlef Schuppan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-03-12       Impact factor: 4.052

Review 4.  Advances in cholangiocyte immunobiology.

Authors:  Gaurav Syal; Michel Fausther; Jonathan A Dranoff
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-09-06       Impact factor: 4.052

Review 5.  Role of NADPH oxidases in liver fibrosis.

Authors:  Yong-Han Paik; Jonghwa Kim; Tomonori Aoyama; Samuele De Minicis; Ramon Bataller; David A Brenner
Journal:  Antioxid Redox Signal       Date:  2014-01-24       Impact factor: 8.401

Review 6.  Role of matrix metalloproteinases in cholestasis and hepatic ischemia/reperfusion injury: A review.

Authors:  Giuseppina Palladini; Andrea Ferrigno; Plinio Richelmi; Stefano Perlini; Mariapia Vairetti
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

Review 7.  Bioconjugation of oligonucleotides for treating liver fibrosis.

Authors:  Zhaoyang Ye; Houssam S Hajj Houssein; Ram I Mahato
Journal:  Oligonucleotides       Date:  2007

8.  The interstitial lymphatic peritoneal mesothelium axis in portal hypertensive ascites: when in danger, go back to the sea.

Authors:  M A Aller; I Prieto; S Argudo; F de Vicente; L Santamaría; M P de Miguel; J L Arias; J Arias
Journal:  Int J Inflam       Date:  2010-10-05

9.  Upregulation of early growth response factor-1 by bile acids requires mitogen-activated protein kinase signaling.

Authors:  Katryn Allen; Nam Deuk Kim; Jeon-Ok Moon; Bryan L Copple
Journal:  Toxicol Appl Pharmacol       Date:  2009-11-17       Impact factor: 4.219

10.  Oxidized low-density-lipoprotein accumulation is associated with liver fibrosis in experimental cholestasis.

Authors:  Güldeniz Karadeniz; Serefden Acikgoz; Ishak Ozel Tekin; Oge Tascýlar; Banu Dogan Gun; Mustafa Cömert
Journal:  Clinics (Sao Paulo)       Date:  2008-08       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.